Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Heres what makes their semaglutide play a potential game-changer Scale over exclusivity Co-marketing deals with leading pharma players underway Multi-brand strategy = faster market penetration + deeper reach First-mover advantage in a post-patent gold rush Early entry into Indias GLP-1 opportunity Aggressive plans to expand across 90+ global markets Device-driven differentiation Pre-filled, disposable pen for easy self-administration Competing not just on molecule but on patient experience Higher-dose roadmap = lifecycle strategy Planned rollout of stronger doses Focus on long-term patient retention & therapy value Beyond pharma: Building a care ecosystem 65 Metabolic Centres of Excellence in the pipeline Driving awareness, adherence, and real-world outcomes Drug + Nutrition = Sticky strategy Targeted nutrition solutions alongside GLP-1 therapy Addressing side effects like muscle loss & appetite changes Premium generic positioning Not the cheapest in the market Competing on quality, convenience & integrated care The real battle is evolving Its no longer just about price
Potential for unknown long-term side effects There is insufficient data on the long-term safety and efficacy of microdosing protocols
Theriogenology 73:10761087
I make sure that patients are supported by a dietician or a formal program (like MOVE!) that helps them make healthy choices
